The Cardioprotective Effects of the Angiotensin-Converting Enzyme Inhibitor Perindopril in Patients With Stable Coronary Artery Disease Are Not Modified by Mild to Moderate Renal InsufficiencyInsights From the EUROPA Trial
Jasper J. Brugts, MD, MSc*,
Eric Boersma, PhD, MSc*,
Michel Chonchol, MD ,
Jaap W. Deckers, MD, PhD*,
Michel Bertrand, MD ,
Willem J. Remme, MD, PhD ,
Roberto Ferrari, MD, PhD||,
Kim Fox, MD¶,
Maarten L. Simoons, MD, PhD*,* EUROPA Investigators
* Department of Cardiology, Thoraxcenter Erasmus Medical Center, Rotterdam, the Netherlands
Department of Renal Disease and Hypertension, University of Colorado, Denver, Colorado
Lille Heart Institute, Lille, France
Sticares Cardiovascular Research Foundation, Rotterdam, the Netherlands
|| Azienda Ospedalier and University di Ferrara, Ferrara, Italy
¶ Royal Brompton and National Heart Hospital, London, United Kingdom
View larger version (17K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Distribution of eGFR in the EUROPA Trial
Distribution of estimated glomerular filtration rate (eGFR) in the EUROPA trial (n = 12,056). MDRD = Modification of Diet in Renal Disease equation.
|
|
View larger version (20K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Kaplan-Meier Estimates of Primary End Point With Perindopril and Placebo According to Baseline eGFR
Kaplan-Meier estimates of the primary end point with perindopril and placebo for different estimated glomerular filtration rates (eGFR) during follow-up (days). The black line corresponds to patients with an eGFR <75 using placebo, and the dotted black line corresponds to patients with an eGFR <75 using perindopril. The red line corresponds to patients with an eGFR  75 using placebo, and the dotted red line corresponds to patients with an eGFR 75 using perindopril. The X-axis represents the follow-up time in days. The Y-axis represents the risk of the primary end point. AMI = acute myocardial infarction.
|
|
|
